The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 26, 2025
Filed:
Mar. 19, 2021
Applicant:
Atux Iskay Llc, Plainsboro, NJ (US);
Inventor:
Michael Ohlmeyer, Plainsboro, NJ (US);
Assignee:
Atux Iskay LLC, Plainsboro, NJ (US);
Primary Examiner:
Int. Cl.
CPC ...
C07D 211/96 (2006.01); C07D 207/08 (2006.01); C07D 207/48 (2006.01); C07D 211/18 (2006.01); C07D 223/04 (2006.01); C07D 241/04 (2006.01); C07D 265/30 (2006.01); C07D 279/12 (2006.01); C07D 417/04 (2006.01);
U.S. Cl.
CPC ...
C07D 211/96 (2013.01); C07D 207/08 (2013.01); C07D 207/48 (2013.01); C07D 211/18 (2013.01); C07D 223/04 (2013.01); C07D 241/04 (2013.01); C07D 265/30 (2013.01); C07D 279/12 (2013.01); C07D 417/04 (2013.01);
Abstract
3-Diarylmethylenes are disclosed. The compounds activate PP2A, suppress oncogenic kinase signaling, and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.